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pregnancy, ectopic pregnancy, suspension because bleeding and other causes, 
and other adverse events by using either LNG-IUS, etonogestrel Implants, 
levonorgestrel implants or copper T (last-two included in health care plan). 
Effectiveness, adverse events and adherence were taken from previously 
published studies and the costs were taken from database of patients in 
Colombia and are expressed in Colombian pesos (COP). An expert gynecologist 
reviewed data. Threshold was estimated in $6.823.583 by calculating the costs 
assigned by the public health care system in Colombia to health care during the 
first five years of life of children and cost of delivery care. A sensitivity analysis 
was developed using a Montecarlo simulation and a Tornado analysis. RESULTS: 
TOTAL OF 13.87 pregnancies occurred with using LNG-IUS as compared with 
40.39 using Copper T, 30.08 using etonorgestrel implant, and 29.55 using 
levonorgestrel implant for the base case analyzed. Cost of LNG-IUS arm was 
COP$ 633,747,545 compared with copper T (COP$ 456,638,680), the less expensive. 
Applying a discount rate of 3% LNG-SIU was dominant versus implant 
etonogestrel and very cost-effective compared with levonorgestrel implant (ICER 
$631,682.98) and cost-effective compared with Copper T (ICER COP$ 6,678,395.53). 
Sensitivity analyses confirm that LNG-UIS keeps its benefits against etonogestrel 
and levonorgestrel in most cases. CONCLUSIONS: The use of LNG-IUS would be 
an adequate option for patients seeking a long-acting contraceptive method and 
its use could be envisaged by the health-care system due to its cost-benefits in 
Colombia.  
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OBJECTIVES: Infection due to respiratory syncytial virus (RSV) is usually 
transient and leaves no sequelae; however, in infants with risk factors such as 
prematurity, bronchopulmonary dysplasia, congenital heart disease or 
infections, it can be more severe, and imply higher costs. Some observational 
studies support the likelihood of an association between RSV and asthma. 
According to the Colombian Medical Federation, palivizumab was one of the ten 
most expensive drugs for the Colombian health system (US$43.6 million in the 4-
year period 2008-11). The aim of this study was to evaluate the cost-effectiveness 
of palivizumab for the treatment of RSV infections in pre-term (<35 weeks) 
infants in Colombia. METHODS: We designed a decision tree model using local 
epidemiological data, effectiveness and safety, as well as QALYs, obtained from 
the scientific literature. We used the third-party payer perspective and a 3% 
discount rate for costs and long term outcomes. The time horizon was the 
lifetime of the patient. RESULTS: In our base case model, compared with no 
prophylaxis palivizumab showed on average an increase in costs per child of 
US$4.895, with 0.1645 QALYs gained, resulting in an incremental cost-
effectiveness ratio of US$29.760 per QALY (our per capita GDP is US$6723). Other 
outcomes of importance in the model were: US$359.962 per asthma case averted, 
US$1.087.884 per life saved and US$75.084 per hospitalization averted. The price 
of paliviumab should be decreased 32% to reach the cost-effectiveness threshold 
of 3-times the per capita GDP. CONCLUSIONS: Under the assumptions and 
results of our study, palivizumab is not a cost-effective intervention and should 
not be recommended for routine immunization in preterm infants of 35 weeks 
gestational age or less, with or without bronchopulmonary dysplasia in 
Colombia.  
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OBJECTIVES: HIV guidelines consider LPV/r a preferred protease inhibitor for use 
during pregnancy. The budget implications of proactively initiating LPV/r versus 
initiating DRV+RTV and then potentially switching to LPV/r upon pregnancy 
were examined. METHODS: A cost minimization analysis was performed (US 
health care perspective) for HIV-1 infected, treatment-naïve WOCBA comparing: 
initiating LPV/r versus initiating DRV+RTV and switching to LPV/r when 
pregnant. A discrete event simulation was employed to represent antiretroviral 
(ARV) therapy management. Clinical trial data were used to model pregnancy 
rates, ARV switch rates, treatment impact as a function of CD4-cell count/viral 
load, adherence, treatment response, acquired resistance mutations, and 
treatment changes. Five- and 10-year costs incurred due to ARV therapy, clinical 
management of AIDS-related, non-AIDS related, and cardiovascular events were 
estimated. Analysis assumptions: switching to LPV/r can occur only once at first 
pregnancy, women’s medication adherence improves 15% at pregnancy and to 
100% if viral rebound. Analyses varied the rate of switching to LPV/r at time of 
pregnancy (0%, 30%, 100%), pregnancy rates, adherence improvement, and 
health care costs. Daily drug cost (WAC): LPV/r + TDF/FTC, $56.59; 
DRV+RTV+TDF/FTC, $73.89. Costs were discounted 3% per annum. RESULTS: 
With 0% switch, survival was similar for LPV/r and DRV+RTV, 7.68 and 7.69 life 
years, respectively (+/- 0.03 QALYs) at 10 years. Five- and 10-year health care 
costs of ARV-naïve WOCBA who initiate LPV/r were $107,790 and $192,352 per 
patient, respectively, versus $132,694 and $235,854 when initiating DRV+RTV (a 
$43,502 per patient savings at 10 years). If 100% of patients who initiated 
DRV+RTV switched to LPV/r upon pregnancy, savings per patient were reduced 
21.3%. Sensitivity analyses showed that initiating LPV/r was always cost-saving 
relative to DRV+RTV. CONCLUSIONS: Initiating HIV infected, treatment-naïve 
WOCBA on LPV/r was cost saving compared to initiating DRV+RTV. Analysis 
limitations include the uncertainty of long-term outcomes projections driven by 
short-term clinical trial endpoints.  
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OBJECTIVES: Labor induction has increasingly been used in the management of 
obstetrical care, owed to post-term pregnancies, maternal/fetal complications 
and voluntary election. Several cervical ripening and induction agents are 
available, though failure or complications with administration of current agents 
are common. Induction failure generally necessitates either additional induction 
agents and/or an eventual cesarean section. This analysis descriptively 
quantifies the economic burden associated with failed medical inductions 
among US Commercial and Medicaid patients. METHODS: A retrospective 
analysis of inpatient hospital discharge data for 2010, using the Healthcare Cost 
and Utilization Project (HCUP) Nationwide Inpatient Sample (NIS) was 
performed, to identify delivery stays with primary or secondary diagnoses of 
failed medical induction (ICD9 659.10-659.13). Rates of cesarean and vaginal 
delivery, average medical charges (converted to costs and displayed in 2010 USD) 
and length of stay per patient are provided. RESULTS: Failed labor induction 
discharges totaled 41,600 in 2010. The average cost for a vaginal delivery (with or 
without complications) after failed induction was $5,890 (average charges of 
$17,645) this is compared to average cost of $3,860 (average charges of $10,106) 
for all vaginal deliveries. Hospital cost for cesareans after failed induction 
averaged $7,595 (average charges of $28,700) compared to $5,990 (average 
charges of $21,875) for all cesarean sections. Average length of stay for failed 
induction with cesarean was 4.42, compared to 3.8 days with vaginal deliveries 
post-induction failure. CONCLUSIONS: Failed medical induction is associated 
with increased risk of cesarean delivery, and associated increased hospital 
resource use, and expenditure in delivery. Preventing complications with 
induction may substantially reduce health care costs and resource utilization.  
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OBJECTIVES: Cost-related medication non-compliance (CRN) is a persistent issue 
that negatively impacts the effectiveness of medical intervention. This study 
aims to evaluate the variation of CRN with functional deficiencies and with 
frequency of hospitalization among the US elderly using a nationally 
representative data set. METHODS: Health Retirement Survey (HRS) 2010 was 
used to assess CRN, deficiencies in Activities of Daily Living (ADL), Instrumental 
Activities of Daily Life (IADL), and frequency of hospitalization over the past 2 
years (0, 1, 2, 3, or 4 or more). CRN was assessed based upon self-reported non-
compliance. After performing bivariate analyses of the association between 
ADLs/IADLs, hospitalizations, insurance coverage, self-reported monthly out-of-
pocket (OOP) payments of prescription drugs and CRN, a logit model was used to 
assess the relationship between CRN and associated risk factors. RESULTS: 2,793 
(12.7%) out of 22,042 elderly reported CRN over a period of 2 years. Those 
reported CRN has a mean ADL deficiencies 0.79 (s.d. 1.43) versus those who did 
not 0.48 (s.d. 1.16) (p<0.001), and a mean IADL deficiencies 0.53 (s.d. 0.97) versus 
those who did not 0.38 (s.d. 0.92) (p<0.001). The logit model showed that 
compared to those who did not have hospitalization, those who had 1 admission 
were 17% more likely to report CRN (p=0.005), those with 2 admissions 14% more 
likely (p=0.10), 3 admissions 54% more likely (p<0.001), and 4 or more admissions 
33% more likely to report CRN (p=0.007). There was an inverse U-shaped 
relationship between CRN and deficiencies in ADLs/IADLs; as ADL/IADL 
deficiencies increased, the likelihood of CRN first increased and then decreased. 
CONCLUSIONS: The positive relationship between number of hospitalization and 
CRN and the inverse U-shaped relationship between functional deficiencies and 
CRN raise concerns that CRN may decrease the effectiveness and increase the 
cost of care in this population.  
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OBJECTIVES: The Women’s Health Initiative (WHI) estrogen+progestin (E+P) 
clinical trial provides a large sample to estimate health state utility values for 
post-menopausal women with an intact uterus in the United States. To facilitate 
future health economic evaluations in this large population sub-group, we 
estimated utilities for trial participants stratified by age group (50-59, 60-69, 70-
79) and randomization assignment (E+P or placebo). METHODS: We measured 
health state utility values for all 16,608 trial participants with the Short Form-6D 
(SF-6D) utility index using a validated Bayesian mapping algorithm and U.S. 
weights. We calculated cross-sectional mean baseline and 1-year utilities, and 
mean within-patient utility change from baseline to 1-year. Patients included in 
the baseline analysis completed the SF-36 within 7 days of randomization, and 
